Condition: Attention Deficit Hyperactivity Disorder (ADHD) · Sponsor: Otsuka Pharmaceutical Co., Ltd.
The purpose of this study is to evaluate the efficacy and examine the safety of two doses of EB-1020 QD XR capsule administered once daily orally in adult ADHD patients.
This description comes directly from the study's public registry record.
Drug Information Center · +81-3-6361-7314
Always discuss trial participation with your own doctor first.
| Maynds Tower Mental Clinic | Tokyo, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06931080